Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
2.970
+0.010 (0.34%)
Mar 3, 2026, 4:00 PM EST - Market closed
Adagene Revenue
Adagene had revenue of $103.20K in the twelve months ending June 30, 2025, down -87.35% year-over-year. In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%.
Revenue (ttm)
$103.20K
Revenue Growth
-87.35%
P/S Ratio
1,356.34
Revenue / Employee
$748
Employees
138
Market Cap
139.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sangamo Therapeutics | 32.88M |
| Zentalis Pharmaceuticals | 26.87M |
| Innate Pharma | 14.84M |
| Whitehawk Therapeutics | 14.38M |
| Connect Biopharma Holdings | 762.00K |
| Artiva Biotherapeutics | 251.00K |
ADAG News
- 14 days ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Adagene Provides Business Update and 2026 Objectives - GlobeNewsWire
- 2 months ago - Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) - GlobeNewsWire
- 3 months ago - Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire
- 4 months ago - Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 6 months ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 6 months ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 6 months ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire